Table 1.
Baseline characteristics of 21 patients initiating TDF/FTC/EVG/cobi plus DRV.
| Characteristic | Value |
|---|---|
| Age – median (IQR) | 43 (33-48) |
| Male – N (%) | 17 (81) |
| Ethnicity – N (%) | |
| Black | 6 (29) |
| White | 15 (71) |
| Duration of HIV diagnosis – median years (IQR) | 15 (3-22) |
| Baseline HIV viral load, copies/mL – median (IQR) | 2635 (0-123137) |
| Patients with baseline HIV viremia (N=15) | 36267 (2206-204478) |
| Baseline CD4 count, cells/mm3 – median (IQR) | 428 (60-579) |
| Patients with baseline HIV viremia (N=15) | 164 (37-447) |
| Patients with baseline HIV-1 RNA < 40 copies/mL (N=6) | 564 (484-849) |
| Baseline CD4 percentage – median (IQR) | 22 (8-27) |
| Patients with baseline HIV viremia (N=15) | 15 (5-24) |
| Patients with baseline HIV-1 RNA < 40 copies/mL (N=6) | 27 (25-35) |
| Treatment-experienced – N (%) | 16 (76) |
| Proportion with baseline HIV-1 RNA <40 copies/mL – N (%) | 6 (38) |
| Years since starting ARV therapy – median (IQR) | 14 (11-17) |
| Number of prior regimens – median (IQR) | 3 (2-5.5) |
| ARV pill burden – median (IQR) | 5 (3-7) |
| Proportion with ARV dosing frequency ≥ twice daily – N (%) | 11 (69) |
| Total pill burden with concurrent meds – median (IQR) | 7.5 (6-9) |
| Number of baseline resistance mutations – median (IQR) | |
| NRTI | 2 (1-4) |
| NNRTI | 1 (1-2) |
| PI | 1 (0-3) |
| INSTI | 0 (0) |
| Number of patients with NRTI-associated mutations – N (%) | |
| Thymidine analogue mutations (TAMs)a | 13 (62) |
| 1 TAM | 2 (10) |
| 2 TAMs | 7 (33) |
| 3 or more TAMs | 4 (19) |
| K65R, 69-insertion complex or Q151M complex | 0 (0) |
| L74V/I | 2 (10) |
| M184V/I | 11 (52) |
| M184V/I with any other major NRTI mutation | 7 (33) |
| No documented NRTI mutations | 3 (14) |
| Number of patients with DRV-associated mutations – N (%) | |
| L33F | 4 (19) |
| Reasons for initiating TDF/FTC/EVG/cobi plus DRVb – N (%) | |
| Treatment-experienced patients | |
| Simplification for pill burden | 14 (67) |
| Simplification for dosing frequency | 11 (52) |
| Non-adherence to previous regimen | 6 (29) |
| Virologic failure to previous regimen | 5 (24) |
| Toxicity/intolerance to previous regimen | 3 (14) |
| Treatment-naïve patients | |
| Baseline resistance | 5 (24) |
Abbreviations: ARV, antiretroviral; DRV, darunavir; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TDF/FTC/EVG/cobi plus DRV, tenofovir disoproxil fumarate, emtricitabine, and cobicistat-boosted elvitegravir plus darunavir.
aTAMs include mutations and revertants at codons 41, 67, 70, 210, 215, and 219.
bReasons among treatment-experienced patients are not mutually exclusive.